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Abstract 
The concept of steric stabilization as used in colloid science is applied to carefully manipulate the drainage and lymphatic distribution of 
subcutaneously administered model polystyrene nanospheres. A wide range of synthetic polyoxyethylene (POE)/polyoxypropylene (POP) block 
co-polymers of poloxamine and poloxamer series have been used to produce sterically stabilized nanospheres. We have found a correlation between 
the length of the stabilizing POE chains of the block co-polymers and nanosphere drainage and passageway across tissue lymph interface in dermal 
lymphatic capillaries in the rat footpads; the longer the POE chains, the faster the particle drainage. Nanospheres conditioned with block co-polymers 
of POE chains of 5-15 ethylene oxide units are effectively opsonized in lymphatics; a process which dramatically enhances equestration (up to 40% 
of the administered ose) by macrophages of the regional lymph nodes. If the dimensions of the stabilizing POE chains of the poloxamines and 
poloxamers exceed the range of the Van der Waals force of attraction, opsonization fails to occur and rapidly drained engineered vehicles escape 
clearance by macrophages of the regional nodes, reach the systemic irculation and remain in the blood for prolonged periods. These observations 
suggest that a lymphatic delivery composition based on polymer-coated particles will be advantageous for many applications in clinical and 
experimental medicine. 
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1. Introduction 2. Materials and methods 
An interstitially administered carrier system for the 
delivery of diagnostic and therapeutic agents to the re- 
gional lymph nodes should have two characteristics. 
Firstly, it should spread well from the injection site and, 
secondly, it should provide good uptake in regional 
nodes. In addition to the integrity of the lymphatic sys- 
tem, it is known that both the particle size and its surface 
characteristics can influence the rate of colloid drainage 
from the subcutaneous injection site into the dermal lym- 
phatic capillaries and phagocytosis by lymph node mac- 
rophages [l-3]. Particles up to 100 nm in diameter are 
preferentially transported into the lymph capillaries and 
phagocytosed in the lymph nodes, whereas larger parti- 
cles will, for a long time, be trapped in the interstitial 
space [2]. However, because of poor drainage, even up- 
take of small particles into regional lymph nodes is gen- 
erally low and values from l-10% of the administered 
dose 2-24 h after subcutaneous administration have been 
reported [l-3]. Here we report that by using the concept 
of steric stabilization [4], it is possible to control the rate 
of drainage from the subcutaneous injection site and 
manipulate the lymphatic distribution of a model parti- 
cle following subcutaneous administration. 
Polystyrene nanospheres, 60 nm in diameter, were purchased from 
Polysciences (UK) and surface labelled with Na[12’I] (Amersham Inter- 
national, UK) as described in detail elsewhere [4,5]. All poloxamines 
and poloxamers were a gift from BASF, USA. The weight average 
polyethylene glycol/polyethylene oxide equivalent molecular mass of 
poloxamines was determined by the method of raised temperature gel- 
permeation chromatography (RAPRA Technology, UK) as described 
in detail elsewhere [6] and was 2,079,3,193 and 22,560 Da for poloxam- 
ine 901, 904 and 908, respectively. The ethylene oxide content (mol%) 
of poloxamines was measured by NMR spectroscopy (Brucker 360 
MHz) in deuterated chloroform by a comparison of the integration 
from the methyl peak (generated from the POP segment of the mole- 
cule) to the total ethylene oxide/propylene oxide signal [6]. The corre- 
sponding values were 20.8%, 50.7% and 88.0% for poloxamine 901,904 
and 908, respectively. Microspheres were coated by preincubation in a 
0.1% (w/v) solution of various poloxamines at room temperature over- 
night. Adsorption of the polymers onto the surface of nanospheres was 
confirmed by measuring the surface potential of nanospheres in 10 mM 
McIlvaine buffer, pH 7.0, [4] by means of Laser Doppler Anemometry 
as described in detail previously [4]. The corresponding zeta potentials 
were -15.6 + 0.3 mV, -5.0 f 0.2 mV and -1.9 f 0.1 mV for poloxam- 
ine 901-, 904- and 908-costed nanospheres, respectively. Excess poly- 
mer was removed by dialysing the nanosphere suspension (Spectrum 
Medical Industries, USA; M, cut-off 100,000) against a large volume 
of de-ionized water. Removal of excess polymer was monitored by the 
iodine assay [7]. The quantity of the polymer adsorbed onto the surface 
of nanospheres was determined from an adsorption isotherm [4] and 
was 74 x 10-s, 50 x lo-’ and 9 x lo-* mol/m’ for poloxamine 901,904 
and 908, respectively. These values represent a surface density of ap- 
proximately 2.2, 3.3 and 18.5 nm’ of polystyrene/molecule of poloxam- 
ine 901, 904 and 908, respectively. 
*Corresponding author. Fax: (44) (602) 515 102. 
Groups of three male Wistar rats, body weight 150 + 10 g, were 
injected subcutaneously into the dorsal surface of the left footpad with 
either uncoated or polymer-coated nanospheres (100 ~1 equivalent to
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0.1 mg of latex nanospheres). 5min before sacrifice 50~1 of patent blue 
dye was injected into the footpad to facilitate easy localization of the 
regional lymph nodes. Finally, rats were sacrificed at various time 
points and the nanosphere-associated ra ioactivity was measured in the 
footpad, regional ymph nodes (which is detined as popliteal, inguinal, 
iliac and renal nodes), blood and organs of the reticuloendothelial 
system. No radioactivity was detected in the right footpad and its 
associated regional nodes. 
Two hours after subcutaneous administration of either uncoated or 
poloxamine coated (904 and 908) nanospheres the intradermal tissue, 
popliteal and iliac nodes were cut into small blocks and immersed in 
fixative (2.5% glutaraldehyde in 0.1 M cacodylate buffer, pH 7.4) for 
4 h. After initial aldehyde fixation the samples were further processed 
in the conventional manner as described in detail elsewhere [4]. Micro- 
graphs were taken with an electron microscope (JEOL 12OOEX) oper- 
ated at 80 kV. Polystyrene spheres do not scatter electrons effectively 
and are thus visualized in the electron microscope as translucent 
spheres. In order to determine whether artifacts were produced by 
tracer particles, animals were injected with 100~1 of water for injection 
or a solution of poloxamine 904 and the tissue was fixed and processed 
for ultrastructural studies. Non-injected animals were also examined. 
3. Results and discussion 
In accordance with previous studies [8] we have used 
small-sized polystyrene nanospheres (60 nm in diameter) 
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as model particles since they are preferentially trans- 
ported into the lymph capillaries and phagocytosed in 
the lymph nodes (Fig. la and b). Specimens observed at 
2 h after subcutaneous injection of control uncoated 
nanospheres revealed extracellular aggregation of the 
particles at the footpad (Fig. 2a) and as a result the 
drainage of nanospheres into initial lymphatics was slow. 
Even at 24 h post-administration approximately 70% of 
the dose remained at the interstitial site (Fig. la). Our 
electron microscopic observations were in accord with 
the earlier studies of Leak [9] and demonstrated that the 
intercellular cleft between adjacent sinusoidal endothe- 
lial cells (patent junction) provided the major route for 
the passage of spheres (micrographs not shown). Macro- 
phages of the regional nodes frequently phagocytosed 
the drained aggregates of nanospheres (Fig. 2b); approx- 
imately 10% and 2% of the dose were sequestered by 
popliteal and iliac nodes, respectively, at 24 h post-ad- 
ministration (Fig. la and b). Serum opsonization of con- 
trol nanospheres reduced the tendency for aggregation 
at the injection site (micrograph not shown) and resulted 
in more rapid dermal clearance (Table 1). 
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Fig. 1. Kinetics of lymph node and organ distribution of uncoated and poloxamine-modified polystyrene spheres following subcutaneous ad- 
ministration into rat footpads. The results are presented as a percentage of the administered ose f S.D. In some cases the error bars are hidden 
within the symbols. Blood values are only shown for uncoated (control) and poloxamine 908~coated (T908) nanospheres since corresponding blood 
values for poloxamine 901- (T901) and poloxamine 904- (T904) coated particles overlaps with that of control nanospheres. In control experiments, 
2 h following subcutaneous administration of free radioactive iodine together with either unlabelled nanospheres or poloxamines or with both 
nanospheres and poloxamines resulted in accumulation of less than 0.2% of the initial dose of radioactivity in the regional ymph nodes. The free 
radiolabel was rapidly cleared from the injection site and became associated with thyroid and bladder and, subsequently, excreted in urine. 
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Fig. 2. Electron micrographs of intradermal tissue and regional ymph node phagocytic ells. (a) Large aggregates of uncoated nanospheres which 
were often found in the intradermal tissue; this process can greatly be minimized by coating the nanospheres with poloxamines and poloxamers; the 
longer the POE chains of the block co-polymers the lesser the tendency for aggregation. Bar = 200 mn. (b) A phagocytic ell of the subcapsular sinus 
from popliteal node containing large amounts of uncoated nanospheres; the cell appears to have sequestered spheres in aggregates ince no 
well-defined lysosomal structures are apparent. Note extracellular aggregates of nanospheres (arrow head) similar to those observed intradermally. 
Bar = 500 nm (c) A phagocytic cell from subcapsular sinus of an iliac node containing large amounts of phagocytosed poloxamine 904-coated 
nanospheres in well-defined lysosomal structures. Bar = 500 nm. (d) A phagocytic ell at intradermal tissue containing phagocytosed nanospheres 
which were opsonized prior to administration; spheres appear to be taken up both in aggregates (arrow) and in non-aggregate form (arrow heads). 
Bar = 500 nm. 
Both the drainage of intradermally injected spheres 
and uptake by the lymph node macrophages can be ma- 
nipulated by conditioning their surface with synthetic 
POE/POP block co-polymers (poloxamines and polo- 
xamers), Fig. la and b. These polymers can adsorb 
strongly onto the surface of polystyrene spheres via their 
hydrophobic POP segments while their hydrophilic POE 
segments extend from the nanosphere surface and pro- 
vide stability to the particle suspension by suppressing 
aggregation (steric stabilization) [4]. We suggest that the 
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rapid drainage of the tested poloxamine-coated nano- 
spheres from the intradermal tissue, when compared to 
that of uncoated particles, may be related to this ‘steric- 
stabilization’ phenomenon (Fig. la and b) [4]. Thus, the 
hydrophilic POE segments of the poloxamines may min- 
imize the interaction of microspheres with the amor- 
phous ground substances or gel-like matrix of the inter- 
stitium and facilitate nanosphere movement hrough the 
water-rich/colloid-poor and colloid-rich/water-poor 
phases, which co-exist within the interstitium [lo], into 
the lymphatics. For effective stabilization of polystyrene 
nanospheres with polyethyleneglycol type materials, it is 
essential that the dimensions of the stabilizing chains of 
the polymers exceed the range of the Van der Waals 
attraction force [4]. These conditions are best met for 
poloxamine 908, rather than that of poloxamine 901 and 
904, and as a result the drainage from the injection site 
of poloxamine 908 is most rapid when compared to that 
of other poloxamines (Fig. la and b) at all time points 
(poloxamines 901, 904 and 908 contain 4, 15 and 119 
ethylene oxide units, respectively, per POE chain, 
whereas they all share a central POP region consisting of 
68 propylene oxide units) [4,5]. These observations can 
also be reproduced with the related poloxamer series 
401, 402 and 407 (Fig. 3). 
Localization of the poloxamine-modified nanospheres 
in regional lymph nodes, particularly in popliteal and 
iliac nodes, is dramatically enhanced for poloxamine 904 
and to a lesser extent for that of poloxamine 901 when 
compared to that of uncoated control spheres at 2 h 
post-administration (Fig. la and b). This distribution 
was even maintained after prolonged hours. Histological 
observations demonstrated that the phagocytic cells of 
the subcapsular sinus of cortex and the classical macro- 
phages of the medula in both the popliteal and iliac 
nodes were mainly responsible for the clearance of these 
poloxamine-coated nanospheres (Fig. 2~). In contrast to 
these poloxamines with low POE chain lengths, coating 
of nanspheres with a poloxamine of a longer POE chain 
(poloxamine 908) dramatically reduced lymph node lo- 
calization and showed increased blood concentration 
when compared to that of uncoated control spheres at 
all time points (Fig. la and b). This observed difference 
in lymph node sequestration among the poloxamine- 
coated particles may be attributed to their different sur- 
face characteristics. The steric barrier imposed by hydro- 
philic POE chains of the poloxamines has been shown to 
suppress both opsonization processes and interaction of 
particles with phagocytic cells; a process which is directly 
proportional to its chain length (the shorter the POE 
chain, the lesser the steric-barrier activity) [4,5]. There- 
fore, it is not surprising that lymph node macrophages 
can efficiently filter the drained poloxamine 901- and 
904-coated particles rather than that of poloxamine 908- 
coated particles during the course of the experiment. 
This concept is further supported by the observation that 
the interstitially administered poloxamine 908-coated 
nanospheres can reach the systemic circulation, remain 
within the blood, and avoid extensive clearance by 
Kupffer cells and spleen macrophages [4,5,8] even at 24 
h post-administration (Fig. la). In contrast, the short 
POE chains of the poloxamine 901 and 904 may, thus, 
allow the opsonization processes to occur, presumably 
in the initial lymphatics, and hence facilitate recognition 
of nanospheres by the node macrophages. This sugges- 
tion is based on the opsonization experiments (Table 1). 
Opsonization of nanospheres in serum prior to admini- 
stration not only enhanced particle retention in both 
popliteal and iliac nodes but also stimulated phagocyto- 
sis by macrophages at the injection site (Fig. 2d) when 
compared to unopsonized control nanospheres. Again, 
the lymph node distribution of nanospheres is not 
poloxamine specific and can be reproduced with the re- 
lated poloxamer family of the appropriate POE chains 
(Fig. 3). 
In summary, we have demonstrated that the concept 
of steric stabilization is beneficial in enhancing lymphatic 
absorption of particulates from the subcutaneous injec- 
Table 1 
Lymphatic distribution of uncoated and poloxamine-coated nanospheres opsonized in serum 
Sites Uptake (%) of administered ose) 
Uncoated 904coated 908-coated 
-serum +serum -serum +serum -serum +serum 
Footpad 14.3 f 11.2 52.2 f 11.3 45.6 + 7.0 32.3 + 5.8 33.4 + 7.8 31.4 f 3.6 
Regional nodes 
Popliteal 3.9 + 0.4 16.4 + 1.6 12.1 f 1.3 10.8 f 2.4 1.3 f 0.6 1.3 + 0.4 
Iliac 0.5 f 0.1 9.6 + 5.4 13.9 f 2.8 18.4 f 2.3 0.7 f 0.2 0.4 + 0.1 
Polystyrene nanospheres (60 nm in diameter) were incubated in 50% (v/v) of autologous erum for 5 min at room temperature before subcutaneous 
administration into rat footpads. Animals were killed 2 h after injection. For experimental details see the legend to Fig. 1. Prior opsonization of 
nanospheres in serum had no effect on circulation time and clearance by organs of the reticuloendothelial system (liver and spleen) and the results 
were comparable to those of unopsonized nanospheres as illustrated in Fig. 1. Total radioactivity recovered at the end of the experiment was more 
than 85% of the administered ose in all cases. 
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Fig. 3. Kinetics of lymph node distribution of uncoated and poloxamer-modified nanospheres following subcutaneous administration into rat 
footpads. Poloxamers 401,402 and 407 contain 5, 11 and 98 ethylene oxide units, respectively, per POE chain, whereas they all share a central POP 
region consisting of 67 propylene oxide units. The corresponding zeta potential values were -8.3 ? 0.8 mV, -16.3 + 1.1 mV and -1.9 f 0.1 mV for 
poloxamer 401-, 4O2- and 407-coated nanospheres, respectively. These polymers were selectively used since their central POP region contain a similar 
number of propylene oxide units to those of the tested poloxamines. Such a high content of propylene oxide units are necessary to anchor the polymers 
firmly onto the surface of nanospheres. For this reason polymers with low content of POP were not used since they can be displaced easily from 
the surface of nanospheres in biological environments [S,lS]. Block co-polymers of poloxamine and poloxamer types containing 2&80 ethylene oxide 
units but sharing a central POP region consisting of 6570 propylene oxide units are not commercially available. For experimental details see legend 
to Fig. 1. 
tion site, but the steric barrier activity should not be too 
strong as this will limit the ability of the regional lymph 
nodes to sequester such engineered particles. We envis- 
age that a lymphatic delivery composition based on pol- 
ymer-coated particles will be advantageous for many ap- 
plications to include vaccine design, studying the kinetics 
of lymph node macrophage re-population following 
selective limination of lymph node phagocytic cells, en- 
hanced imaging and visualisation modalities (lym- 
phoscintigraphy and X-ray), radiation therapy for abla- 
tion of metastatic diseases, and site-specific delivery of 
drugs and therapeutic agents for prevention of tumour 
metastases and for treatment of various lymph node dis- 
eases particularly of those agents which accumulate or 
hide in macrophages (such as human immunodeficiency 
virus, filariasis, and brucellosis) [2,3,1 l-l 31. Biodegrada- 
ble carriers based on poloxamine 908 or poloxamer 407 
may provide an alternative route for the delivery of ther- 
apeutic agents to the systemic circulation and may be 
used as a sustained release system [14]. 
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